Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal
growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study
will test an experimental drug called DS-8201a that has not been approved by the health
authorities yet.
DS-8201a will be tested for safety in patients with advanced solid malignant tumors that test
positive for HER2. It also will test how DS-8201a moves within the body (pharmacokinetics).